C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on May 20, 2021. The filing discloses significant changes to the company's executive leadership, specifically the appointment of a new Chief Financial Officer and the interim arrangement following the resignation of the Principal Accounting Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of CFO: Lauren White was appointed as Chief Financial Officer, Treasurer, Principal Financial Officer, and Principal Accounting Officer, effective June 21, 2021.
- Resignation of Principal Accounting Officer: Laura J. Wahlberg resigned as VP, Finance, Corporate Controller, and Principal Accounting Officer, effective May 28, 2021.
- Interim Leadership: Current CFO William T. McKee will serve as interim Principal Accounting Officer until Ms. White's start date and will remain as a consultant until July 2, 2021.
Compensation and Management Commentary
Ms. White's compensation package includes:
- Annual base salary of $415,000.
- Sign-on bonus of $60,000.
- Performance bonus opportunity of up to 40% of base salary.
- Stock option to purchase 136,000 shares at the closing price on the effective date, vesting monthly over four years with a one-year cliff.
Ms. White brings over 20 years of experience, most recently from Novartis. Mr. McKee, who has served as CFO since April 2020, will transition to a consulting role to ensure an orderly handover.
Investor Verification Checklist
- Verify the exact start date of Lauren White's employment (June 21, 2021) and the vesting schedule of her stock options.
- Confirm the transition timeline for William T. McKee's consulting role ending July 2, 2021.
- Review the employment agreement (Exhibit 10.7) and indemnification agreement (Exhibit 10.6) referenced in the filing for additional terms.
- Check subsequent filings for any updates to the company's financial status or pipeline progress, as this 8-K contains no operational or financial metrics.